nodes	percent_of_prediction	percent_of_DWPC	metapath
Lisuride—Pulmonary fibrosis—Chlorambucil—ovarian cancer	0.0278	0.0359	CcSEcCtD
Lisuride—Pulmonary fibrosis—Melphalan—ovarian cancer	0.0242	0.0313	CcSEcCtD
Lisuride—Peripheral coldness—Vinorelbine—ovarian cancer	0.0195	0.0253	CcSEcCtD
Lisuride—HTR2A—vein—ovarian cancer	0.0178	0.096	CbGeAlD
Lisuride—Pulmonary fibrosis—Paclitaxel—ovarian cancer	0.0142	0.0184	CcSEcCtD
Lisuride—Pleural effusion—Topotecan—ovarian cancer	0.0142	0.0184	CcSEcCtD
Lisuride—Vertigo—Altretamine—ovarian cancer	0.0135	0.0175	CcSEcCtD
Lisuride—Peripheral coldness—Paclitaxel—ovarian cancer	0.0131	0.017	CcSEcCtD
Lisuride—Pericardial effusion—Docetaxel—ovarian cancer	0.0129	0.0167	CcSEcCtD
Lisuride—Pulmonary fibrosis—Docetaxel—ovarian cancer	0.0121	0.0156	CcSEcCtD
Lisuride—Anorexia—Altretamine—ovarian cancer	0.0117	0.0151	CcSEcCtD
Lisuride—Decreased appetite—Altretamine—ovarian cancer	0.0107	0.0138	CcSEcCtD
Lisuride—Fatigue—Altretamine—ovarian cancer	0.0106	0.0137	CcSEcCtD
Lisuride—Asthenia—Altretamine—ovarian cancer	0.0088	0.0114	CcSEcCtD
Lisuride—Pericardial effusion—Epirubicin—ovarian cancer	0.00872	0.0113	CcSEcCtD
Lisuride—DRD4—testis—ovarian cancer	0.00842	0.0453	CbGeAlD
Lisuride—Infection—Carboplatin—ovarian cancer	0.00842	0.0109	CcSEcCtD
Lisuride—Pericarditis—Epirubicin—ovarian cancer	0.00827	0.0107	CcSEcCtD
Lisuride—Pleural effusion—Paclitaxel—ovarian cancer	0.00817	0.0106	CcSEcCtD
Lisuride—Dizziness—Altretamine—ovarian cancer	0.00811	0.0105	CcSEcCtD
Lisuride—Pericardial effusion—Doxorubicin—ovarian cancer	0.00807	0.0104	CcSEcCtD
Lisuride—Vomiting—Altretamine—ovarian cancer	0.0078	0.0101	CcSEcCtD
Lisuride—Pericarditis—Doxorubicin—ovarian cancer	0.00765	0.0099	CcSEcCtD
Lisuride—ADRA1D—epithelium—ovarian cancer	0.00742	0.0399	CbGeAlD
Lisuride—Pleural effusion—Docetaxel—ovarian cancer	0.00693	0.00896	CcSEcCtD
Lisuride—DRD5—female reproductive system—ovarian cancer	0.00687	0.037	CbGeAlD
Lisuride—HTR2B—myometrium—ovarian cancer	0.00657	0.0354	CbGeAlD
Lisuride—Blood pressure increased—Paclitaxel—ovarian cancer	0.00626	0.0081	CcSEcCtD
Lisuride—DRD5—female gonad—ovarian cancer	0.00625	0.0337	CbGeAlD
Lisuride—Weight increased—Topotecan—ovarian cancer	0.00621	0.00804	CcSEcCtD
Lisuride—Hallucination—Chlorambucil—ovarian cancer	0.0061	0.0079	CcSEcCtD
Lisuride—Sweating—Topotecan—ovarian cancer	0.00583	0.00755	CcSEcCtD
Lisuride—ADRA1D—female reproductive system—ovarian cancer	0.00551	0.0297	CbGeAlD
Lisuride—Blood pressure increased—Docetaxel—ovarian cancer	0.0053	0.00686	CcSEcCtD
Lisuride—Weight decreased—Vinorelbine—ovarian cancer	0.00528	0.00683	CcSEcCtD
Lisuride—ADRA2C—myometrium—ovarian cancer	0.00517	0.0279	CbGeAlD
Lisuride—HTR2B—uterine cervix—ovarian cancer	0.00511	0.0275	CbGeAlD
Lisuride—Angiopathy—Topotecan—ovarian cancer	0.00495	0.00641	CcSEcCtD
Lisuride—Immune system disorder—Topotecan—ovarian cancer	0.00493	0.00638	CcSEcCtD
Lisuride—Mediastinal disorder—Topotecan—ovarian cancer	0.00492	0.00637	CcSEcCtD
Lisuride—HTR2B—decidua—ovarian cancer	0.00487	0.0262	CbGeAlD
Lisuride—Immune system disorder—Melphalan—ovarian cancer	0.00483	0.00625	CcSEcCtD
Lisuride—Mediastinal disorder—Melphalan—ovarian cancer	0.00482	0.00624	CcSEcCtD
Lisuride—Malnutrition—Topotecan—ovarian cancer	0.00475	0.00615	CcSEcCtD
Lisuride—Pleural effusion—Epirubicin—ovarian cancer	0.00467	0.00605	CcSEcCtD
Lisuride—HTR2B—endometrium—ovarian cancer	0.00462	0.0249	CbGeAlD
Lisuride—Confusional state—Chlorambucil—ovarian cancer	0.00439	0.00569	CcSEcCtD
Lisuride—Cardiac disorder—Vinorelbine—ovarian cancer	0.00434	0.00561	CcSEcCtD
Lisuride—Infection—Chlorambucil—ovarian cancer	0.00433	0.0056	CcSEcCtD
Lisuride—Pleural effusion—Doxorubicin—ovarian cancer	0.00432	0.00559	CcSEcCtD
Lisuride—HTR2B—uterus—ovarian cancer	0.00426	0.023	CbGeAlD
Lisuride—HTR1B—female reproductive system—ovarian cancer	0.00425	0.0229	CbGeAlD
Lisuride—Angiopathy—Vinorelbine—ovarian cancer	0.00424	0.00549	CcSEcCtD
Lisuride—Dehydration—Paclitaxel—ovarian cancer	0.00422	0.00547	CcSEcCtD
Lisuride—Immune system disorder—Vinorelbine—ovarian cancer	0.00422	0.00546	CcSEcCtD
Lisuride—Mediastinal disorder—Vinorelbine—ovarian cancer	0.00421	0.00545	CcSEcCtD
Lisuride—Anorexia—Chlorambucil—ovarian cancer	0.00415	0.00538	CcSEcCtD
Lisuride—Orthostatic hypotension—Paclitaxel—ovarian cancer	0.00415	0.00537	CcSEcCtD
Lisuride—Cough—Topotecan—ovarian cancer	0.00415	0.00537	CcSEcCtD
Lisuride—ADRA2A—myometrium—ovarian cancer	0.00413	0.0222	CbGeAlD
Lisuride—HTR1D—female reproductive system—ovarian cancer	0.00412	0.0222	CbGeAlD
Lisuride—HTR2C—female reproductive system—ovarian cancer	0.00408	0.022	CbGeAlD
Lisuride—Malnutrition—Vinorelbine—ovarian cancer	0.00407	0.00526	CcSEcCtD
Lisuride—Cough—Melphalan—ovarian cancer	0.00406	0.00526	CcSEcCtD
Lisuride—ADRA2C—uterine cervix—ovarian cancer	0.00402	0.0217	CbGeAlD
Lisuride—ADRB1—female reproductive system—ovarian cancer	0.004	0.0216	CbGeAlD
Lisuride—Infection—Topotecan—ovarian cancer	0.00385	0.00499	CcSEcCtD
Lisuride—ADRA2C—decidua—ovarian cancer	0.00383	0.0207	CbGeAlD
Lisuride—HTR2B—female reproductive system—ovarian cancer	0.00383	0.0206	CbGeAlD
Lisuride—Nervous system disorder—Topotecan—ovarian cancer	0.0038	0.00492	CcSEcCtD
Lisuride—Decreased appetite—Chlorambucil—ovarian cancer	0.00379	0.0049	CcSEcCtD
Lisuride—Infection—Melphalan—ovarian cancer	0.00377	0.00488	CcSEcCtD
Lisuride—Gastrointestinal disorder—Chlorambucil—ovarian cancer	0.00376	0.00487	CcSEcCtD
Lisuride—Fatigue—Chlorambucil—ovarian cancer	0.00376	0.00486	CcSEcCtD
Lisuride—Hyperhidrosis—Topotecan—ovarian cancer	0.00375	0.00485	CcSEcCtD
Lisuride—Tachycardia—Melphalan—ovarian cancer	0.00371	0.0048	CcSEcCtD
Lisuride—Anorexia—Topotecan—ovarian cancer	0.0037	0.00479	CcSEcCtD
Lisuride—Vertigo—Vinorelbine—ovarian cancer	0.00365	0.00473	CcSEcCtD
Lisuride—ADRA2C—endometrium—ovarian cancer	0.00364	0.0196	CbGeAlD
Lisuride—Anorexia—Melphalan—ovarian cancer	0.00362	0.00469	CcSEcCtD
Lisuride—Palpitations—Vinorelbine—ovarian cancer	0.00359	0.00465	CcSEcCtD
Lisuride—Feeling abnormal—Chlorambucil—ovarian cancer	0.00359	0.00465	CcSEcCtD
Lisuride—Dehydration—Docetaxel—ovarian cancer	0.00358	0.00463	CcSEcCtD
Lisuride—Weight increased—Paclitaxel—ovarian cancer	0.00357	0.00462	CcSEcCtD
Lisuride—Weight decreased—Paclitaxel—ovarian cancer	0.00355	0.0046	CcSEcCtD
Lisuride—Cough—Vinorelbine—ovarian cancer	0.00355	0.00459	CcSEcCtD
Lisuride—Orthostatic hypotension—Docetaxel—ovarian cancer	0.00352	0.00455	CcSEcCtD
Lisuride—HTR2B—vagina—ovarian cancer	0.00346	0.0187	CbGeAlD
Lisuride—Dyspnoea—Topotecan—ovarian cancer	0.00346	0.00448	CcSEcCtD
Lisuride—Dyspnoea—Melphalan—ovarian cancer	0.00339	0.00438	CcSEcCtD
Lisuride—HTR2A—embryo—ovarian cancer	0.00338	0.0182	CbGeAlD
Lisuride—Decreased appetite—Topotecan—ovarian cancer	0.00337	0.00436	CcSEcCtD
Lisuride—ADRA2C—uterus—ovarian cancer	0.00335	0.0181	CbGeAlD
Lisuride—Gastrointestinal disorder—Topotecan—ovarian cancer	0.00335	0.00433	CcSEcCtD
Lisuride—Fatigue—Topotecan—ovarian cancer	0.00334	0.00433	CcSEcCtD
Lisuride—Constipation—Topotecan—ovarian cancer	0.00332	0.00429	CcSEcCtD
Lisuride—Decreased appetite—Melphalan—ovarian cancer	0.0033	0.00427	CcSEcCtD
Lisuride—Infection—Vinorelbine—ovarian cancer	0.0033	0.00427	CcSEcCtD
Lisuride—Gastrointestinal disorder—Melphalan—ovarian cancer	0.00328	0.00424	CcSEcCtD
Lisuride—Fatigue—Melphalan—ovarian cancer	0.00328	0.00424	CcSEcCtD
Lisuride—Nervous system disorder—Vinorelbine—ovarian cancer	0.00325	0.00421	CcSEcCtD
Lisuride—Tachycardia—Vinorelbine—ovarian cancer	0.00324	0.00419	CcSEcCtD
Lisuride—ADRA2A—uterine cervix—ovarian cancer	0.00321	0.0173	CbGeAlD
Lisuride—Feeling abnormal—Topotecan—ovarian cancer	0.0032	0.00414	CcSEcCtD
Lisuride—Anorexia—Vinorelbine—ovarian cancer	0.00316	0.00409	CcSEcCtD
Lisuride—Asthenia—Chlorambucil—ovarian cancer	0.00313	0.00405	CcSEcCtD
Lisuride—Oedema peripheral—Paclitaxel—ovarian cancer	0.0031	0.00401	CcSEcCtD
Lisuride—ADRA2A—decidua—ovarian cancer	0.00306	0.0165	CbGeAlD
Lisuride—Weight increased—Docetaxel—ovarian cancer	0.00303	0.00392	CcSEcCtD
Lisuride—Weight decreased—Docetaxel—ovarian cancer	0.00301	0.0039	CcSEcCtD
Lisuride—Dyspnoea—Vinorelbine—ovarian cancer	0.00296	0.00383	CcSEcCtD
Lisuride—Cardiac disorder—Paclitaxel—ovarian cancer	0.00292	0.00377	CcSEcCtD
Lisuride—ADRA2A—endometrium—ovarian cancer	0.0029	0.0156	CbGeAlD
Lisuride—Decreased appetite—Vinorelbine—ovarian cancer	0.00289	0.00373	CcSEcCtD
Lisuride—Gastrointestinal disorder—Vinorelbine—ovarian cancer	0.00287	0.00371	CcSEcCtD
Lisuride—Fatigue—Vinorelbine—ovarian cancer	0.00286	0.0037	CcSEcCtD
Lisuride—Angiopathy—Paclitaxel—ovarian cancer	0.00285	0.00369	CcSEcCtD
Lisuride—Constipation—Vinorelbine—ovarian cancer	0.00284	0.00367	CcSEcCtD
Lisuride—Immune system disorder—Paclitaxel—ovarian cancer	0.00284	0.00367	CcSEcCtD
Lisuride—Mediastinal disorder—Paclitaxel—ovarian cancer	0.00283	0.00366	CcSEcCtD
Lisuride—Asthenia—Topotecan—ovarian cancer	0.00278	0.0036	CcSEcCtD
Lisuride—Vomiting—Chlorambucil—ovarian cancer	0.00277	0.00359	CcSEcCtD
Lisuride—HTR2A—epithelium—ovarian cancer	0.00275	0.0148	CbGeAlD
Lisuride—Mental disorder—Paclitaxel—ovarian cancer	0.00275	0.00356	CcSEcCtD
Lisuride—ADRA2C—female gonad—ovarian cancer	0.00274	0.0148	CbGeAlD
Lisuride—Malnutrition—Paclitaxel—ovarian cancer	0.00274	0.00354	CcSEcCtD
Lisuride—Feeling abnormal—Vinorelbine—ovarian cancer	0.00273	0.00354	CcSEcCtD
Lisuride—ADRA2C—vagina—ovarian cancer	0.00273	0.0147	CbGeAlD
Lisuride—Asthenia—Melphalan—ovarian cancer	0.00273	0.00353	CcSEcCtD
Lisuride—ADRA2A—gonad—ovarian cancer	0.00269	0.0145	CbGeAlD
Lisuride—ADRA2A—uterus—ovarian cancer	0.00268	0.0144	CbGeAlD
Lisuride—Oedema peripheral—Docetaxel—ovarian cancer	0.00262	0.0034	CcSEcCtD
Lisuride—Dizziness—Topotecan—ovarian cancer	0.00257	0.00332	CcSEcCtD
Lisuride—DRD2—testis—ovarian cancer	0.0025	0.0135	CbGeAlD
Lisuride—Cardiac disorder—Docetaxel—ovarian cancer	0.00247	0.0032	CcSEcCtD
Lisuride—Vomiting—Topotecan—ovarian cancer	0.00247	0.00319	CcSEcCtD
Lisuride—Vertigo—Paclitaxel—ovarian cancer	0.00246	0.00318	CcSEcCtD
Lisuride—Syncope—Paclitaxel—ovarian cancer	0.00245	0.00317	CcSEcCtD
Lisuride—ADRA2C—testis—ovarian cancer	0.00243	0.0131	CbGeAlD
Lisuride—Headache—Topotecan—ovarian cancer	0.00243	0.00315	CcSEcCtD
Lisuride—Palpitations—Paclitaxel—ovarian cancer	0.00242	0.00313	CcSEcCtD
Lisuride—Angiopathy—Docetaxel—ovarian cancer	0.00242	0.00313	CcSEcCtD
Lisuride—Vomiting—Melphalan—ovarian cancer	0.00242	0.00313	CcSEcCtD
Lisuride—Dehydration—Epirubicin—ovarian cancer	0.00241	0.00313	CcSEcCtD
Lisuride—ADRA2A—female reproductive system—ovarian cancer	0.00241	0.013	CbGeAlD
Lisuride—Immune system disorder—Docetaxel—ovarian cancer	0.00241	0.00311	CcSEcCtD
Lisuride—Mediastinal disorder—Docetaxel—ovarian cancer	0.0024	0.00311	CcSEcCtD
Lisuride—Cough—Paclitaxel—ovarian cancer	0.00239	0.00309	CcSEcCtD
Lisuride—Asthenia—Vinorelbine—ovarian cancer	0.00238	0.00308	CcSEcCtD
Lisuride—Orthostatic hypotension—Epirubicin—ovarian cancer	0.00237	0.00307	CcSEcCtD
Lisuride—Mental disorder—Docetaxel—ovarian cancer	0.00233	0.00302	CcSEcCtD
Lisuride—Anxiety—Paclitaxel—ovarian cancer	0.00232	0.003	CcSEcCtD
Lisuride—Malnutrition—Docetaxel—ovarian cancer	0.00232	0.003	CcSEcCtD
Lisuride—HTR2A—gonad—ovarian cancer	0.00229	0.0123	CbGeAlD
Lisuride—Dry mouth—Paclitaxel—ovarian cancer	0.00228	0.00295	CcSEcCtD
Lisuride—Confusional state—Paclitaxel—ovarian cancer	0.00225	0.00291	CcSEcCtD
Lisuride—HTR2B—lymph node—ovarian cancer	0.00224	0.0121	CbGeAlD
Lisuride—Dehydration—Doxorubicin—ovarian cancer	0.00223	0.00289	CcSEcCtD
Lisuride—Infection—Paclitaxel—ovarian cancer	0.00222	0.00287	CcSEcCtD
Lisuride—Dizziness—Vinorelbine—ovarian cancer	0.00219	0.00284	CcSEcCtD
Lisuride—Orthostatic hypotension—Doxorubicin—ovarian cancer	0.00219	0.00284	CcSEcCtD
Lisuride—ADRA2A—female gonad—ovarian cancer	0.00219	0.0118	CbGeAlD
Lisuride—Nervous system disorder—Paclitaxel—ovarian cancer	0.00219	0.00283	CcSEcCtD
Lisuride—Tachycardia—Paclitaxel—ovarian cancer	0.00218	0.00282	CcSEcCtD
Lisuride—ADRA2A—vagina—ovarian cancer	0.00218	0.0117	CbGeAlD
Lisuride—Hyperhidrosis—Paclitaxel—ovarian cancer	0.00216	0.00279	CcSEcCtD
Lisuride—Anorexia—Paclitaxel—ovarian cancer	0.00213	0.00275	CcSEcCtD
Lisuride—Vomiting—Vinorelbine—ovarian cancer	0.00211	0.00273	CcSEcCtD
Lisuride—Headache—Vinorelbine—ovarian cancer	0.00208	0.00269	CcSEcCtD
Lisuride—Syncope—Docetaxel—ovarian cancer	0.00208	0.00269	CcSEcCtD
Lisuride—Palpitations—Docetaxel—ovarian cancer	0.00205	0.00265	CcSEcCtD
Lisuride—HTR2A—female reproductive system—ovarian cancer	0.00205	0.011	CbGeAlD
Lisuride—Weight increased—Epirubicin—ovarian cancer	0.00204	0.00264	CcSEcCtD
Lisuride—Weight decreased—Epirubicin—ovarian cancer	0.00203	0.00263	CcSEcCtD
Lisuride—Cough—Docetaxel—ovarian cancer	0.00202	0.00262	CcSEcCtD
Lisuride—Insomnia—Paclitaxel—ovarian cancer	0.00202	0.00261	CcSEcCtD
Lisuride—Dyspnoea—Paclitaxel—ovarian cancer	0.00199	0.00258	CcSEcCtD
Lisuride—Somnolence—Paclitaxel—ovarian cancer	0.00198	0.00257	CcSEcCtD
Lisuride—ADRA2A—testis—ovarian cancer	0.00194	0.0105	CbGeAlD
Lisuride—Decreased appetite—Paclitaxel—ovarian cancer	0.00194	0.00251	CcSEcCtD
Lisuride—Dry mouth—Docetaxel—ovarian cancer	0.00193	0.0025	CcSEcCtD
Lisuride—Gastrointestinal disorder—Paclitaxel—ovarian cancer	0.00193	0.00249	CcSEcCtD
Lisuride—Fatigue—Paclitaxel—ovarian cancer	0.00192	0.00249	CcSEcCtD
Lisuride—Sweating—Epirubicin—ovarian cancer	0.00192	0.00248	CcSEcCtD
Lisuride—Constipation—Paclitaxel—ovarian cancer	0.00191	0.00247	CcSEcCtD
Lisuride—Confusional state—Docetaxel—ovarian cancer	0.00191	0.00247	CcSEcCtD
Lisuride—CYP3A4—female reproductive system—ovarian cancer	0.00189	0.0102	CbGeAlD
Lisuride—Weight increased—Doxorubicin—ovarian cancer	0.00189	0.00245	CcSEcCtD
Lisuride—Infection—Docetaxel—ovarian cancer	0.00188	0.00243	CcSEcCtD
Lisuride—Weight decreased—Doxorubicin—ovarian cancer	0.00188	0.00243	CcSEcCtD
Lisuride—CYP2D6—female reproductive system—ovarian cancer	0.00186	0.01	CbGeAlD
Lisuride—Nervous system disorder—Docetaxel—ovarian cancer	0.00186	0.0024	CcSEcCtD
Lisuride—HTR2A—vagina—ovarian cancer	0.00185	0.00996	CbGeAlD
Lisuride—Tachycardia—Docetaxel—ovarian cancer	0.00185	0.00239	CcSEcCtD
Lisuride—Feeling abnormal—Paclitaxel—ovarian cancer	0.00184	0.00238	CcSEcCtD
Lisuride—Anorexia—Docetaxel—ovarian cancer	0.0018	0.00233	CcSEcCtD
Lisuride—Sweating—Doxorubicin—ovarian cancer	0.00178	0.0023	CcSEcCtD
Lisuride—Oedema peripheral—Epirubicin—ovarian cancer	0.00177	0.00229	CcSEcCtD
Lisuride—ADRA2C—lymph node—ovarian cancer	0.00176	0.0095	CbGeAlD
Lisuride—Insomnia—Docetaxel—ovarian cancer	0.00171	0.00221	CcSEcCtD
Lisuride—CYP2D6—female gonad—ovarian cancer	0.0017	0.00913	CbGeAlD
Lisuride—Dyspnoea—Docetaxel—ovarian cancer	0.00169	0.00218	CcSEcCtD
Lisuride—Somnolence—Docetaxel—ovarian cancer	0.00168	0.00218	CcSEcCtD
Lisuride—Cardiac disorder—Epirubicin—ovarian cancer	0.00167	0.00216	CcSEcCtD
Lisuride—HTR2A—testis—ovarian cancer	0.00165	0.00889	CbGeAlD
Lisuride—Decreased appetite—Docetaxel—ovarian cancer	0.00164	0.00213	CcSEcCtD
Lisuride—Oedema peripheral—Doxorubicin—ovarian cancer	0.00164	0.00212	CcSEcCtD
Lisuride—Ergonovine—ABCB1—ovarian cancer	0.00164	0.64	CrCbGaD
Lisuride—Gastrointestinal disorder—Docetaxel—ovarian cancer	0.00163	0.00211	CcSEcCtD
Lisuride—Fatigue—Docetaxel—ovarian cancer	0.00163	0.00211	CcSEcCtD
Lisuride—Angiopathy—Epirubicin—ovarian cancer	0.00163	0.00211	CcSEcCtD
Lisuride—Immune system disorder—Epirubicin—ovarian cancer	0.00162	0.0021	CcSEcCtD
Lisuride—Mediastinal disorder—Epirubicin—ovarian cancer	0.00162	0.0021	CcSEcCtD
Lisuride—Constipation—Docetaxel—ovarian cancer	0.00162	0.00209	CcSEcCtD
Lisuride—Asthenia—Paclitaxel—ovarian cancer	0.0016	0.00207	CcSEcCtD
Lisuride—Mental disorder—Epirubicin—ovarian cancer	0.00157	0.00204	CcSEcCtD
Lisuride—Malnutrition—Epirubicin—ovarian cancer	0.00156	0.00202	CcSEcCtD
Lisuride—Feeling abnormal—Docetaxel—ovarian cancer	0.00156	0.00202	CcSEcCtD
Lisuride—Cardiac disorder—Doxorubicin—ovarian cancer	0.00154	0.002	CcSEcCtD
Lisuride—Angiopathy—Doxorubicin—ovarian cancer	0.00151	0.00195	CcSEcCtD
Lisuride—CYP2D6—testis—ovarian cancer	0.0015	0.0081	CbGeAlD
Lisuride—Immune system disorder—Doxorubicin—ovarian cancer	0.0015	0.00194	CcSEcCtD
Lisuride—Mediastinal disorder—Doxorubicin—ovarian cancer	0.0015	0.00194	CcSEcCtD
Lisuride—Dizziness—Paclitaxel—ovarian cancer	0.00148	0.00191	CcSEcCtD
Lisuride—Mental disorder—Doxorubicin—ovarian cancer	0.00146	0.00188	CcSEcCtD
Lisuride—Malnutrition—Doxorubicin—ovarian cancer	0.00145	0.00187	CcSEcCtD
Lisuride—Vomiting—Paclitaxel—ovarian cancer	0.00142	0.00184	CcSEcCtD
Lisuride—ADRA2A—lymph node—ovarian cancer	0.00141	0.00758	CbGeAlD
Lisuride—Vertigo—Epirubicin—ovarian cancer	0.0014	0.00182	CcSEcCtD
Lisuride—Syncope—Epirubicin—ovarian cancer	0.0014	0.00181	CcSEcCtD
Lisuride—Headache—Paclitaxel—ovarian cancer	0.0014	0.00181	CcSEcCtD
Lisuride—Palpitations—Epirubicin—ovarian cancer	0.00138	0.00179	CcSEcCtD
Lisuride—Cough—Epirubicin—ovarian cancer	0.00136	0.00177	CcSEcCtD
Lisuride—Asthenia—Docetaxel—ovarian cancer	0.00136	0.00176	CcSEcCtD
Lisuride—Anxiety—Epirubicin—ovarian cancer	0.00133	0.00172	CcSEcCtD
Lisuride—Dry mouth—Epirubicin—ovarian cancer	0.0013	0.00169	CcSEcCtD
Lisuride—Vertigo—Doxorubicin—ovarian cancer	0.0013	0.00168	CcSEcCtD
Lisuride—Syncope—Doxorubicin—ovarian cancer	0.0013	0.00168	CcSEcCtD
Lisuride—Confusional state—Epirubicin—ovarian cancer	0.00129	0.00167	CcSEcCtD
Lisuride—Palpitations—Doxorubicin—ovarian cancer	0.00128	0.00165	CcSEcCtD
Lisuride—Infection—Epirubicin—ovarian cancer	0.00127	0.00164	CcSEcCtD
Lisuride—Cough—Doxorubicin—ovarian cancer	0.00126	0.00163	CcSEcCtD
Lisuride—Nervous system disorder—Epirubicin—ovarian cancer	0.00125	0.00162	CcSEcCtD
Lisuride—Dizziness—Docetaxel—ovarian cancer	0.00125	0.00162	CcSEcCtD
Lisuride—Tachycardia—Epirubicin—ovarian cancer	0.00125	0.00161	CcSEcCtD
Lisuride—Hyperhidrosis—Epirubicin—ovarian cancer	0.00123	0.0016	CcSEcCtD
Lisuride—Anxiety—Doxorubicin—ovarian cancer	0.00123	0.00159	CcSEcCtD
Lisuride—Anorexia—Epirubicin—ovarian cancer	0.00122	0.00157	CcSEcCtD
Lisuride—Dry mouth—Doxorubicin—ovarian cancer	0.0012	0.00156	CcSEcCtD
Lisuride—Vomiting—Docetaxel—ovarian cancer	0.0012	0.00156	CcSEcCtD
Lisuride—Confusional state—Doxorubicin—ovarian cancer	0.00119	0.00154	CcSEcCtD
Lisuride—Headache—Docetaxel—ovarian cancer	0.00119	0.00153	CcSEcCtD
Lisuride—Infection—Doxorubicin—ovarian cancer	0.00117	0.00152	CcSEcCtD
Lisuride—Nervous system disorder—Doxorubicin—ovarian cancer	0.00116	0.0015	CcSEcCtD
Lisuride—Insomnia—Epirubicin—ovarian cancer	0.00115	0.00149	CcSEcCtD
Lisuride—Tachycardia—Doxorubicin—ovarian cancer	0.00115	0.00149	CcSEcCtD
Lisuride—Hyperhidrosis—Doxorubicin—ovarian cancer	0.00114	0.00148	CcSEcCtD
Lisuride—Dyspnoea—Epirubicin—ovarian cancer	0.00114	0.00147	CcSEcCtD
Lisuride—Somnolence—Epirubicin—ovarian cancer	0.00113	0.00147	CcSEcCtD
Lisuride—Anorexia—Doxorubicin—ovarian cancer	0.00113	0.00146	CcSEcCtD
Lisuride—Decreased appetite—Epirubicin—ovarian cancer	0.00111	0.00144	CcSEcCtD
Lisuride—Gastrointestinal disorder—Epirubicin—ovarian cancer	0.0011	0.00143	CcSEcCtD
Lisuride—Fatigue—Epirubicin—ovarian cancer	0.0011	0.00142	CcSEcCtD
Lisuride—Constipation—Epirubicin—ovarian cancer	0.00109	0.00141	CcSEcCtD
Lisuride—Insomnia—Doxorubicin—ovarian cancer	0.00107	0.00138	CcSEcCtD
Lisuride—Dyspnoea—Doxorubicin—ovarian cancer	0.00105	0.00136	CcSEcCtD
Lisuride—Feeling abnormal—Epirubicin—ovarian cancer	0.00105	0.00136	CcSEcCtD
Lisuride—Somnolence—Doxorubicin—ovarian cancer	0.00105	0.00136	CcSEcCtD
Lisuride—Decreased appetite—Doxorubicin—ovarian cancer	0.00103	0.00133	CcSEcCtD
Lisuride—Gastrointestinal disorder—Doxorubicin—ovarian cancer	0.00102	0.00132	CcSEcCtD
Lisuride—Fatigue—Doxorubicin—ovarian cancer	0.00102	0.00132	CcSEcCtD
Lisuride—Constipation—Doxorubicin—ovarian cancer	0.00101	0.00131	CcSEcCtD
Lisuride—Feeling abnormal—Doxorubicin—ovarian cancer	0.000973	0.00126	CcSEcCtD
Lisuride—Ergotamine—ABCB1—ovarian cancer	0.000922	0.36	CrCbGaD
Lisuride—Asthenia—Epirubicin—ovarian cancer	0.000916	0.00119	CcSEcCtD
Lisuride—Asthenia—Doxorubicin—ovarian cancer	0.000847	0.0011	CcSEcCtD
Lisuride—Dizziness—Epirubicin—ovarian cancer	0.000844	0.00109	CcSEcCtD
Lisuride—Vomiting—Epirubicin—ovarian cancer	0.000811	0.00105	CcSEcCtD
Lisuride—Headache—Epirubicin—ovarian cancer	0.0008	0.00103	CcSEcCtD
Lisuride—Dizziness—Doxorubicin—ovarian cancer	0.000781	0.00101	CcSEcCtD
Lisuride—Vomiting—Doxorubicin—ovarian cancer	0.000751	0.000972	CcSEcCtD
Lisuride—Headache—Doxorubicin—ovarian cancer	0.00074	0.000957	CcSEcCtD
Lisuride—HTR1A—Signaling Pathways—MMP9—ovarian cancer	6.24e-06	0.00016	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—MAPK1—ovarian cancer	6.22e-06	0.000159	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CCND1—ovarian cancer	6.22e-06	0.000159	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—EGFR—ovarian cancer	6.22e-06	0.000159	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MMP9—ovarian cancer	6.21e-06	0.000159	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PTEN—ovarian cancer	6.2e-06	0.000159	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CB—ovarian cancer	6.2e-06	0.000159	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MTOR—ovarian cancer	6.2e-06	0.000159	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PTEN—ovarian cancer	6.17e-06	0.000158	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK3—ovarian cancer	6.16e-06	0.000158	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—CTNNB1—ovarian cancer	6.16e-06	0.000158	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—KRAS—ovarian cancer	6.15e-06	0.000158	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CCND1—ovarian cancer	6.12e-06	0.000157	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK3—ovarian cancer	6.08e-06	0.000156	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK3—ovarian cancer	6.08e-06	0.000156	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—CTNNB1—ovarian cancer	6.06e-06	0.000155	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CXCL8—ovarian cancer	6.05e-06	0.000155	CbGpPWpGaD
Lisuride—HTR1A—Signaling by GPCR—AKT1—ovarian cancer	6.05e-06	0.000155	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MMP9—ovarian cancer	6.04e-06	0.000155	CbGpPWpGaD
Lisuride—HTR2C—Signaling by GPCR—AKT1—ovarian cancer	6.02e-06	0.000154	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—HRAS—ovarian cancer	6.02e-06	0.000154	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PTEN—ovarian cancer	6e-06	0.000154	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MYC—ovarian cancer	5.99e-06	0.000153	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CXCL8—ovarian cancer	5.96e-06	0.000153	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MMP9—ovarian cancer	5.94e-06	0.000152	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—HRAS—ovarian cancer	5.92e-06	0.000152	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MYC—ovarian cancer	5.91e-06	0.000151	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MYC—ovarian cancer	5.91e-06	0.000151	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CDKN1B—ovarian cancer	5.91e-06	0.000151	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PTEN—ovarian cancer	5.91e-06	0.000151	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—KRAS—ovarian cancer	5.87e-06	0.00015	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—PIK3CA—ovarian cancer	5.86e-06	0.00015	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—MAPK1—ovarian cancer	5.86e-06	0.00015	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—EGFR—ovarian cancer	5.86e-06	0.00015	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—VEGFA—ovarian cancer	5.86e-06	0.00015	CbGpPWpGaD
Lisuride—ADRA2C—Signaling by GPCR—AKT1—ovarian cancer	5.85e-06	0.00015	CbGpPWpGaD
Lisuride—DRD2—GPCR downstream signaling—AKT1—ovarian cancer	5.85e-06	0.00015	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PTEN—ovarian cancer	5.83e-06	0.000149	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—PIK3CA—ovarian cancer	5.82e-06	0.000149	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CDKN1B—ovarian cancer	5.82e-06	0.000149	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—VEGFA—ovarian cancer	5.8e-06	0.000149	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—STAT3—ovarian cancer	5.8e-06	0.000148	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CASP3—ovarian cancer	5.8e-06	0.000148	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL2—ovarian cancer	5.79e-06	0.000148	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—MAPK1—ovarian cancer	5.78e-06	0.000148	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—MAPK1—ovarian cancer	5.78e-06	0.000148	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—NRAS—ovarian cancer	5.78e-06	0.000148	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—EGFR—ovarian cancer	5.78e-06	0.000148	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—EGFR—ovarian cancer	5.78e-06	0.000148	CbGpPWpGaD
Lisuride—ADRA1B—Signaling by GPCR—AKT1—ovarian cancer	5.76e-06	0.000148	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—IL6—ovarian cancer	5.76e-06	0.000147	CbGpPWpGaD
Lisuride—HTR2A—GPCR downstream signaling—AKT1—ovarian cancer	5.76e-06	0.000147	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—STAT3—ovarian cancer	5.74e-06	0.000147	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—PIK3CA—ovarian cancer	5.74e-06	0.000147	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CG—ovarian cancer	5.74e-06	0.000147	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—NRAS—ovarian cancer	5.73e-06	0.000147	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—ERBB2—ovarian cancer	5.72e-06	0.000146	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CASP3—ovarian cancer	5.7e-06	0.000146	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL2—ovarian cancer	5.69e-06	0.000146	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—TP53—ovarian cancer	5.67e-06	0.000145	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—IL6—ovarian cancer	5.66e-06	0.000145	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—PIK3CA—ovarian cancer	5.65e-06	0.000145	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CCND1—ovarian cancer	5.64e-06	0.000144	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MTOR—ovarian cancer	5.64e-06	0.000144	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CB—ovarian cancer	5.64e-06	0.000144	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PPP2R1A—ovarian cancer	5.6e-06	0.000144	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—VEGFA—ovarian cancer	5.6e-06	0.000143	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—CTNNB1—ovarian cancer	5.59e-06	0.000143	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—VEGFA—ovarian cancer	5.57e-06	0.000143	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—TP53—ovarian cancer	5.56e-06	0.000142	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CCND1—ovarian cancer	5.55e-06	0.000142	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—STAT3—ovarian cancer	5.55e-06	0.000142	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK3—ovarian cancer	5.54e-06	0.000142	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—KRAS—ovarian cancer	5.54e-06	0.000142	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—NRAS—ovarian cancer	5.53e-06	0.000142	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—STAT3—ovarian cancer	5.52e-06	0.000141	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—NRAS—ovarian cancer	5.5e-06	0.000141	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—CTNNB1—ovarian cancer	5.5e-06	0.000141	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK3—ovarian cancer	5.49e-06	0.000141	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MMP9—ovarian cancer	5.48e-06	0.00014	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—TP53—ovarian cancer	5.47e-06	0.00014	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—KRAS—ovarian cancer	5.46e-06	0.00014	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—KRAS—ovarian cancer	5.46e-06	0.00014	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PTEN—ovarian cancer	5.44e-06	0.000139	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—HRAS—ovarian cancer	5.43e-06	0.000139	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CXCL8—ovarian cancer	5.42e-06	0.000139	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—VEGFA—ovarian cancer	5.42e-06	0.000139	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—PIK3CA—ovarian cancer	5.39e-06	0.000138	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MMP9—ovarian cancer	5.39e-06	0.000138	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MYC—ovarian cancer	5.39e-06	0.000138	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—HRAS—ovarian cancer	5.38e-06	0.000138	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—STAT3—ovarian cancer	5.37e-06	0.000137	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PTEN—ovarian cancer	5.36e-06	0.000137	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—NRAS—ovarian cancer	5.35e-06	0.000137	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MYC—ovarian cancer	5.34e-06	0.000137	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—VEGFA—ovarian cancer	5.33e-06	0.000137	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—HRAS—ovarian cancer	5.31e-06	0.000136	CbGpPWpGaD
Lisuride—DRD2—Signaling by GPCR—AKT1—ovarian cancer	5.31e-06	0.000136	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK3—ovarian cancer	5.3e-06	0.000136	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CDKN1B—ovarian cancer	5.29e-06	0.000136	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—STAT3—ovarian cancer	5.28e-06	0.000135	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK3—ovarian cancer	5.27e-06	0.000135	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—MAPK1—ovarian cancer	5.27e-06	0.000135	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—EGFR—ovarian cancer	5.27e-06	0.000135	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—NRAS—ovarian cancer	5.27e-06	0.000135	CbGpPWpGaD
Lisuride—ADRA2A—GPCR downstream signaling—AKT1—ovarian cancer	5.24e-06	0.000134	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—HRAS—ovarian cancer	5.23e-06	0.000134	CbGpPWpGaD
Lisuride—HTR2A—Signaling by GPCR—AKT1—ovarian cancer	5.23e-06	0.000134	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—MAPK1—ovarian cancer	5.22e-06	0.000134	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—EGFR—ovarian cancer	5.22e-06	0.000134	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—TP53—ovarian cancer	5.22e-06	0.000134	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—ABCB1—ovarian cancer	5.2e-06	0.000133	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—IL6—ovarian cancer	5.19e-06	0.000133	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CASP3—ovarian cancer	5.19e-06	0.000133	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL2—ovarian cancer	5.18e-06	0.000133	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—IL6—ovarian cancer	5.15e-06	0.000132	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MYC—ovarian cancer	5.15e-06	0.000132	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK3—ovarian cancer	5.13e-06	0.000131	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MYC—ovarian cancer	5.13e-06	0.000131	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—TYMS—ovarian cancer	5.11e-06	0.000131	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—PIK3CA—ovarian cancer	5.09e-06	0.00013	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—IL6—ovarian cancer	5.09e-06	0.00013	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—PIK3CA—ovarian cancer	5.06e-06	0.00013	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CCND1—ovarian cancer	5.05e-06	0.000129	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK3—ovarian cancer	5.05e-06	0.000129	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CD—ovarian cancer	5.04e-06	0.000129	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—MAPK1—ovarian cancer	5.04e-06	0.000129	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—EGFR—ovarian cancer	5.04e-06	0.000129	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—PIK3CA—ovarian cancer	5.02e-06	0.000129	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—PIK3CA—ovarian cancer	5.02e-06	0.000129	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—MAPK1—ovarian cancer	5.02e-06	0.000128	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—EGFR—ovarian cancer	5.01e-06	0.000128	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—IL6—ovarian cancer	5e-06	0.000128	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—CTNNB1—ovarian cancer	5e-06	0.000128	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—HRAS—ovarian cancer	4.99e-06	0.000128	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MYC—ovarian cancer	4.99e-06	0.000128	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—KRAS—ovarian cancer	4.98e-06	0.000127	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—KRAS—ovarian cancer	4.93e-06	0.000126	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—TP53—ovarian cancer	4.92e-06	0.000126	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—VEGFA—ovarian cancer	4.92e-06	0.000126	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MYC—ovarian cancer	4.91e-06	0.000126	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MMP9—ovarian cancer	4.9e-06	0.000126	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—MAPK1—ovarian cancer	4.88e-06	0.000125	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—EGFR—ovarian cancer	4.88e-06	0.000125	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PTEN—ovarian cancer	4.87e-06	0.000125	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—STAT3—ovarian cancer	4.87e-06	0.000125	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—NRAS—ovarian cancer	4.86e-06	0.000124	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—TP53—ovarian cancer	4.86e-06	0.000124	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—TP53—ovarian cancer	4.86e-06	0.000124	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—VEGFA—ovarian cancer	4.84e-06	0.000124	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—MAPK1—ovarian cancer	4.8e-06	0.000123	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—EGFR—ovarian cancer	4.8e-06	0.000123	CbGpPWpGaD
Lisuride—HTR1D—Signaling Pathways—AKT1—ovarian cancer	4.79e-06	0.000123	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—STAT3—ovarian cancer	4.79e-06	0.000123	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—NRAS—ovarian cancer	4.78e-06	0.000122	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—IL6—ovarian cancer	4.78e-06	0.000122	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—KRAS—ovarian cancer	4.76e-06	0.000122	CbGpPWpGaD
Lisuride—ADRA2A—Signaling by GPCR—AKT1—ovarian cancer	4.75e-06	0.000122	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—KRAS—ovarian cancer	4.74e-06	0.000121	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—HRAS—ovarian cancer	4.71e-06	0.000121	CbGpPWpGaD
Lisuride—HTR1B—Signaling Pathways—AKT1—ovarian cancer	4.69e-06	0.00012	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK3—ovarian cancer	4.65e-06	0.000119	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—HRAS—ovarian cancer	4.64e-06	0.000119	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—HRAS—ovarian cancer	4.64e-06	0.000119	CbGpPWpGaD
Lisuride—DRD4—Signaling Pathways—AKT1—ovarian cancer	4.62e-06	0.000118	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—KRAS—ovarian cancer	4.61e-06	0.000118	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK3—ovarian cancer	4.58e-06	0.000117	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—PIK3CA—ovarian cancer	4.57e-06	0.000117	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—KRAS—ovarian cancer	4.53e-06	0.000116	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—PIK3CA—ovarian cancer	4.53e-06	0.000116	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MYC—ovarian cancer	4.52e-06	0.000116	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—IL6—ovarian cancer	4.5e-06	0.000115	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MYC—ovarian cancer	4.45e-06	0.000114	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—IL6—ovarian cancer	4.44e-06	0.000114	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—IL6—ovarian cancer	4.44e-06	0.000114	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—MAPK1—ovarian cancer	4.43e-06	0.000113	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—EGFR—ovarian cancer	4.43e-06	0.000113	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—TP53—ovarian cancer	4.42e-06	0.000113	CbGpPWpGaD
Lisuride—HTR2B—Signaling Pathways—AKT1—ovarian cancer	4.41e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—VEGFA—ovarian cancer	4.4e-06	0.000113	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CB—ovarian cancer	4.4e-06	0.000113	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—TP53—ovarian cancer	4.38e-06	0.000112	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—PIK3CA—ovarian cancer	4.37e-06	0.000112	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—STAT3—ovarian cancer	4.36e-06	0.000112	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—MAPK1—ovarian cancer	4.36e-06	0.000112	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—EGFR—ovarian cancer	4.35e-06	0.000112	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—PIK3CA—ovarian cancer	4.35e-06	0.000111	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—NRAS—ovarian cancer	4.35e-06	0.000111	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—PIK3CA—ovarian cancer	4.23e-06	0.000108	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—TP53—ovarian cancer	4.23e-06	0.000108	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—HRAS—ovarian cancer	4.23e-06	0.000108	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—TP53—ovarian cancer	4.21e-06	0.000108	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—HRAS—ovarian cancer	4.19e-06	0.000107	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—KRAS—ovarian cancer	4.18e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—PIK3CA—ovarian cancer	4.17e-06	0.000107	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK3—ovarian cancer	4.16e-06	0.000107	CbGpPWpGaD
Lisuride—DRD1—Signaling Pathways—AKT1—ovarian cancer	4.16e-06	0.000106	CbGpPWpGaD
Lisuride—ADRA2C—Metabolism—AKT1—ovarian cancer	4.14e-06	0.000106	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—CAV1—ovarian cancer	4.12e-06	0.000105	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—KRAS—ovarian cancer	4.11e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—PIK3CA—ovarian cancer	4.11e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA1D—Signaling Pathways—AKT1—ovarian cancer	4.1e-06	0.000105	CbGpPWpGaD
Lisuride—DRD3—Signaling Pathways—AKT1—ovarian cancer	4.1e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—TP53—ovarian cancer	4.1e-06	0.000105	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MYC—ovarian cancer	4.05e-06	0.000104	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—IL6—ovarian cancer	4.05e-06	0.000104	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—HRAS—ovarian cancer	4.05e-06	0.000104	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—TP53—ovarian cancer	4.03e-06	0.000103	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—HRAS—ovarian cancer	4.03e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—IL6—ovarian cancer	4.01e-06	0.000103	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—MAPK1—ovarian cancer	3.96e-06	0.000101	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—EGFR—ovarian cancer	3.96e-06	0.000101	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—HRAS—ovarian cancer	3.92e-06	0.0001	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—IL6—ovarian cancer	3.87e-06	9.92e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—HRAS—ovarian cancer	3.85e-06	9.87e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—IL6—ovarian cancer	3.85e-06	9.87e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—PIK3CA—ovarian cancer	3.84e-06	9.84e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PTEN—ovarian cancer	3.8e-06	9.73e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—PIK3CA—ovarian cancer	3.78e-06	9.68e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CG—ovarian cancer	3.75e-06	9.61e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—IL6—ovarian cancer	3.75e-06	9.6e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—KRAS—ovarian cancer	3.74e-06	9.59e-05	CbGpPWpGaD
Lisuride—ADRB1—Signaling Pathways—AKT1—ovarian cancer	3.74e-06	9.57e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—TP53—ovarian cancer	3.72e-06	9.52e-05	CbGpPWpGaD
Lisuride—ADRA2B—Signaling Pathways—AKT1—ovarian cancer	3.7e-06	9.48e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—IL6—ovarian cancer	3.69e-06	9.45e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—TP53—ovarian cancer	3.66e-06	9.36e-05	CbGpPWpGaD
Lisuride—HTR1A—Signaling Pathways—AKT1—ovarian cancer	3.57e-06	9.15e-05	CbGpPWpGaD
Lisuride—HTR2C—Signaling Pathways—AKT1—ovarian cancer	3.56e-06	9.11e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—HRAS—ovarian cancer	3.55e-06	9.1e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—HRAS—ovarian cancer	3.5e-06	8.96e-05	CbGpPWpGaD
Lisuride—ADRA2C—Signaling Pathways—AKT1—ovarian cancer	3.46e-06	8.86e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—PIK3CA—ovarian cancer	3.44e-06	8.81e-05	CbGpPWpGaD
Lisuride—ADRA1B—Signaling Pathways—AKT1—ovarian cancer	3.4e-06	8.72e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—IL6—ovarian cancer	3.4e-06	8.71e-05	CbGpPWpGaD
Lisuride—ADRA2A—Metabolism—AKT1—ovarian cancer	3.36e-06	8.6e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—IL6—ovarian cancer	3.35e-06	8.57e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—TP53—ovarian cancer	3.33e-06	8.52e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CD—ovarian cancer	3.3e-06	8.44e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—HRAS—ovarian cancer	3.18e-06	8.15e-05	CbGpPWpGaD
Lisuride—DRD2—Signaling Pathways—AKT1—ovarian cancer	3.14e-06	8.04e-05	CbGpPWpGaD
Lisuride—HTR2A—Signaling Pathways—AKT1—ovarian cancer	3.09e-06	7.91e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—IL6—ovarian cancer	3.04e-06	7.8e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CB—ovarian cancer	2.87e-06	7.36e-05	CbGpPWpGaD
Lisuride—ADRA2A—Signaling Pathways—AKT1—ovarian cancer	2.81e-06	7.19e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—PIK3CA—ovarian cancer	2.68e-06	6.86e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PTEN—ovarian cancer	2.48e-06	6.36e-05	CbGpPWpGaD
Lisuride—CYP2D6—Metabolism—AKT1—ovarian cancer	2.19e-06	5.61e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—PIK3CA—ovarian cancer	1.75e-06	4.49e-05	CbGpPWpGaD
Lisuride—CYP3A4—Metabolism—AKT1—ovarian cancer	1.43e-06	3.67e-05	CbGpPWpGaD
